The gut microbiome, ageing and longevity in dogs and cats.

Dogs and cats are living longer, and that changes the question.

For most of veterinary history the practical problem with an old dog or cat was getting them to old age at all. That problem has softened. Using the electronic records of more than 1,000 Banfield hospitals across the United States, Montoya and colleagues (2023) built life expectancy tables from 13,292,929 dogs and 2,390,078 cats and reported a life expectancy at birth of 12.69 years for dogs (95% CI 12.68 to 12.70) and 11.18 years for cats (11.16 to 11.20). Those are population averages that fold in early deaths, so a dog or cat that reaches adulthood in a well-run home can expect considerably more.

Longer lives bring a different set of problems. Banfield's State of Pet Health 2016 Report, drawn from 2.5 million dogs and 500,000 cats, recorded dental disease in 76 per cent of dogs and 68 per cent of cats, and a 79.7 per cent rise in canine diabetes since 2006. These are the diseases of animals that live long enough to accumulate them. The same body condition that shortens life shows up in the life expectancy tables: obese dogs at a body condition score of 5 out of 5 had a life expectancy at birth of 11.71 years against 13.18 years for dogs at an ideal 3 out of 5 (Montoya et al. 2023). The pattern in cats is less clean, with overweight cats in that study living longest, a reminder that the tidy story in dogs does not always transfer species to species.

So the question is no longer only how to keep a pet alive. It is how to keep the added years good ones, and where in the body the levers for that might sit. One candidate that has moved from the fringe to serious geroscience over the past decade is the gut microbiome.

What ageing does, from the brain to the muscles.

Before asking whether the microbiome matters, it helps to be specific about what ageing actually does to a dog or a cat, because the target is not a single disease.

In the brain, dogs develop canine cognitive dysfunction syndrome, a progressive neurodegenerative condition with clear parallels to human Alzheimer's disease. The Canine Cognitive Dysfunction Syndrome Working Group (Olby et al. 2026) defines it through the behavioural domains captured by the acronym DISHAA, disorientation, altered social interaction, sleep disruption, house soiling, altered activity, and anxiety, and describes its neuropathology of cortical atrophy, hippocampal neuron loss and amyloid-beta plaques. The Working Group recommends senior behavioural screening from seven years of age and a structured cognitive rating scale from ten. Prevalence is not trivial. Reviewing the field, Chapagain and colleagues (2018) put the prevalence of cognitive dysfunction in dogs over eight years at 14.2 to 22.5 per cent, rising exponentially with age, and noted the gap between how often it occurs and how often it is diagnosed: one cited survey found signs in 14.2 per cent of aged pet dogs against a veterinary diagnosis rate of 1.9 per cent. In the same body of work, 28 per cent of dogs aged 11 to 12 years showed impairment in at least one behavioural category, rising to 68 per cent at 15 to 16 years.

In the body, the story is muscle and frailty. The 2021 AAFP Feline Senior Care Guidelines (Ray et al. 2021) treat frailty as a syndrome in its own right, a loss of functional reserve that leaves an older cat more vulnerable to everything else, and single out sarcopenia, the age-related loss of muscle mass and strength that occurs independently of disease. Cats age faster than we do: the guidelines note that a healthy adult cat examined at a human-equivalent frequency would be seen every ten to eleven weeks, and recommend twice-yearly examinations for cats aged 10 to 15. Body composition is not a cosmetic matter. In a ten-year prospective study of 39 Labrador retrievers, Adams and colleagues (2016) found that lifelong maintenance of lean body mass and slower accumulation of body fat were the factors that separated dogs reaching an exceptional lifespan, defined as 15.6 years or more, from those living a merely expected span. In that cohort, 28.2 per cent of dogs reached exceptional longevity.

And ageing costs quality of life in a way owners feel directly. Using the Canine Owner-Reported Quality of Life Questionnaire, Mondino and colleagues (2024) studied 92 dogs cross-sectionally and followed 34 longitudinally. Quality of life fell as dogs approached the end of their expected lifespan, the vitality domain suffered most, and a score below 5.35 out of 7 was associated with a higher risk of death. Cats have their own validated instrument: Noble and colleagues (2019) developed and tested a generic feline quality-of-life questionnaire that correctly classified 78 per cent of cats as healthy or sick. There is even a longevity paradox waiting in the wings. Sarver and colleagues (2022) argue that dogs and humans now live two to four times beyond the lifespan their cancer-protective biology evolved to cover, which is part of why roughly one in four dogs develops cancer and why cancer is a leading cause of death in pets past middle age.

None of these papers mention the microbiome. They are here to make the target concrete. Ageing in dogs and cats is cognitive decline, sarcopenia and frailty, falling quality of life, and a rising burden of chronic disease. Any claim that the gut has something to offer has to connect to that list, not to an abstraction.

The ageing gut changes in a consistent direction.

The gut microbiome is not fixed. It is shaped through life by diet, environment, medication and age, and the age-related part has a recognisable shape. Reviewing the mechanistic links between the microbiome and ageing, Garzon-Escamilla and colleagues (2026) describe a broadly consistent human pattern in later life: reductions in Bifidobacterium and in the butyrate-producing members of the Firmicutes, alongside increases in Proteobacteria and Fusobacteria. Dysbiosis, an imbalanced and less resilient community, is now discussed as one of the recognised hallmarks of ageing rather than a downstream curiosity.

The companion-animal picture is thinner but not empty. In a review of companion animal nutrition, Deng and Swanson (2015) describe the core bacterial phyla of the canine and feline gut and, importantly for ageing work, summarise experimental evidence that both age and diet change gene expression across multiple tissues in dogs, comparing aged animals around twelve years with young animals around one year, in the brain, the colon, the liver, fat and skeletal muscle. Two points follow from that. The first is that the ageing signal in a dog is not confined to the gut; it is readable in tissues throughout the body, which is what a systemic, microbiome-linked process would predict. The second is that diet, the single input an owner most controls, is also one of the strongest levers on the gut community at any age. A shift in the microbiome with age is therefore never age alone; it is age acting through a lifetime of diet, environment and medication.

The tools to study the ageing gut in dogs and cats exist. What is missing, and this matters for everything that follows, is a large, well-controlled canine or feline dataset that tracks the same animals' microbiomes across their lifespan and links those changes to how well or how long they live. That study has been done in mice and, in a different form, in rabbits. It has not yet been done properly in dogs and cats.

What Barcena 2019 found, in two lines of progeroid mice.

The single most direct piece of causal evidence that the gut microbiome can move the needle on lifespan comes from mice engineered to age prematurely. Barcena and colleagues (2019) worked with two progeroid models, one carrying the Lmna G609G mutation of Hutchinson-Gilford progeria and one lacking Zmpste24. Both showed intestinal dysbiosis, with more Proteobacteria and fewer Verrucomicrobia than healthy littermates, mirroring in miniature the shift seen in ageing humans.

The causal test was a faecal microbiota transplant. Transplanting the gut community of healthy wild-type mice into progeroid recipients extended their lives. In the Lmna model, median lifespan rose from 141 to 160 days, an increase of about 13.5 per cent (P = 0.0029), and the effect held in the Zmpste24 model as well. The direction of causation was confirmed from the other side: transplanting the community of an old progeroid donor shortened recipients' lives. The team then narrowed the effect to a single organism. Giving Akkermansia muciniphila on its own, by oral gavage, was enough to extend the lifespan of progeroid mice (P = 0.016), and it did so while thickening the intestinal mucus layer and restoring markers of gut barrier integrity. The proposed mechanism ran through the restoration of secondary bile acids, metabolites the gut community produces that the host cannot make alone.

Two cautions travel with this result and should not be dropped. First, these are mice with an accelerated-ageing mutation, not normally ageing animals, and certainly not dogs or cats. Second, the same paper reported that human centenarians tend to carry more Verrucomicrobia, including Akkermansia, and fewer Proteobacteria than younger adults, which is an association in people, not an intervention. The mouse work is causal and striking; its species and its model both sit some distance from a fifteen-year-old cat.

What Biada 2024 found, in 95 rabbits.

A second line of evidence comes from an animal bred, over generations, for long productive life. Biada and colleagues (2024) studied 95 rabbit does from two maternal lines, one selected for longevity across many parities and one standard line, and profiled their gut microbiomes by 16S ribosomal RNA sequencing. The longevity-selected line carried a more diverse gut community, with significantly higher Shannon diversity (P = 0.001). A supervised classification model separated the two lines on their microbiome alone with better than 91 per cent accuracy, which means the difference is substantial and structured rather than noise.

The taxa doing the discriminating are the interesting part. The longer-lived line was enriched for Akkermansia and for the Christensenellaceae R-7 group, among others. This is a different species, a different selection pressure and a different method from the mouse work, and it lands on overlapping organisms. That kind of convergence, arrived at independently, is worth more than any single study. It is also, again, not a dog or a cat, and it is a correlation between breeding line and microbiome rather than a transplant experiment. It tells us the association is real and reproducible across species; it does not by itself tell us the microbes are the cause of the longevity.

The microbes that keep reappearing in long-lived animals.

Step back from the individual studies and a short list of names recurs. Akkermansia muciniphila extends lifespan in progeroid mice (Barcena et al. 2019), is enriched in the longevity-selected rabbit line (Biada et al. 2024), and is among the organisms increased in human centenarians and reduced in ageing (Garzon-Escamilla et al. 2026). Christensenellaceae appears in the rabbit longevity signature and in the centenarian literature. Butyrate-producing Firmicutes decline with age and are the organisms most consistently tied to a healthy gut barrier.

It would be a mistake to read this as a recipe. The same reviews are candid that the associations are context-dependent, that Akkermansia is not uniformly beneficial in every disease setting, and that a taxon being abundant in long-lived animals does not prove that adding it will lengthen life. What the convergence does establish is that ageing is not microbiologically random. Across mice, rabbits and people, longer and healthier lives are associated with a more diverse community and with a recognisable set of barrier-supporting, metabolite-producing organisms. That is a real signal. Whether it is a lever, and whether that lever exists in dogs and cats, are the next two questions.

How the gut reaches the rest of the body: barrier, LPS and short-chain fatty acids.

For a gut community to affect ageing anywhere else, there has to be a route out of the intestine. Three connected mechanisms recur across the literature and give the association its plausibility.

The first is the barrier. A single layer of epithelial cells, coated in mucus, separates a dense microbial population from the body's circulation. With age that barrier tends to weaken. When it does, bacterial products cross into the bloodstream, and the most studied of these is lipopolysaccharide, a component of the outer membrane of Gram-negative bacteria. Circulating lipopolysaccharide drives low-grade, persistent immune activation, the state often called inflammaging, and chronic inflammation is itself one of the drivers of age-related disease. This is why the barrier-supporting effect of Akkermansia in Barcena's mice, thickening the mucus and tightening the barrier, is mechanistically meaningful rather than incidental.

The second is short-chain fatty acids. When gut bacteria ferment dietary fibre they produce butyrate, acetate and propionate. Butyrate in particular is the preferred fuel of colonic epithelial cells, supports the barrier from the inside, and has anti-inflammatory effects. The age-related loss of butyrate-producing bacteria therefore removes a support the ageing gut needs more, not less. Reviewing biotic interventions in dogs and cats, Wilson and Swanson (2024) place short-chain fatty acid production and immune modulation at the centre of why the gut community matters for companion-animal health.

The third is metabolic signalling, of which the secondary bile acids in Barcena's mice are one example. The gut community chemically transforms host and dietary molecules into signalling compounds the host responds to systemically. This is the general form of the argument: the microbiome is not sealed in the gut, it is a metabolic organ whose outputs reach the immune system, the brain and the rest of the body. The barrier, the short-chain fatty acids and the bile acids are three worked examples of the same principle.

These mechanisms also explain why a gut effect, if it exists in dogs and cats, would not be confined to digestion. Chronic low-grade inflammation is a shared driver across the ageing conditions named earlier. It contributes to the neuroinflammation described in canine cognitive dysfunction (Olby et al. 2026), to the permissive, inflamed tissue environments that Sarver and colleagues (2022) tie to age-related cancer, and to the muscle loss of sarcopenia and frailty in senior cats (Ray et al. 2021). A gut that leaks more lipopolysaccharide and produces less butyrate with age is, in principle, feeding that same inflammatory current. This is why the microbiome is discussed as a lever on ageing in general rather than on any single organ: it sits upstream of a process that touches many of them at once. It is also why the argument remains, for dogs and cats, a mechanistic expectation rather than a demonstrated fact.

Longevity drugs may work partly through the gut.

One of the more surprising threads in recent geroscience is that several of the interventions being studied to slow ageing appear to act, in part, by reshaping the gut microbiome. Garzon-Escamilla and colleagues (2026) review this for a series of candidate longevity therapeutics.

Metformin, the diabetes drug with the longest track record as a candidate geroprotective agent, consistently changes the gut community, increasing Akkermansia and short-chain fatty acid producers and strengthening the intestinal barrier, to the point where some of its metabolic effect is thought to run through the gut rather than around it. Rapamycin, senolytic combinations such as dasatinib plus quercetin, GLP-1 receptor agonists, and the natural polyamine spermidine all show gut-remodelling effects in animal models, and they converge, again, on Akkermansia, on short-chain fatty acids, and on improved barrier integrity.

The honest reading of this section is double-edged, and both edges matter. It is encouraging that independent anti-ageing interventions keep landing on the same microbial features, because it suggests those features are close to the biology of ageing rather than incidental to it. But the same review is careful to note that the microbiome changes are not always necessary for the lifespan effect. In one experiment, transferring the rapamycin-altered microbiome of treated flies into untreated flies did not transfer the longevity benefit. The microbiome is part of how these drugs work; it is not the whole of it, and it is not proven to be the active ingredient. None of these agents is a companion-animal longevity treatment, and this post is not a suggestion to use any of them in a dog or cat.

What we can and cannot say about dogs and cats.

Here is where honesty earns its place. The direct, causal, longevity-extending microbiome evidence is in mice. The reproducible longevity-associated microbiome signature is in rabbits and people. The mechanistic scaffolding, barrier, lipopolysaccharide, short-chain fatty acids, bile acids, is general mammalian biology and almost certainly applies to dogs and cats. What does not yet exist is the study that closes the loop in the species that matter here.

No published work shows that changing a dog's or a cat's gut microbiome extends its healthspan or its lifespan. What exists for dogs and cats is the demographic reality that they are living longer (Montoya et al. 2023), a detailed picture of what ageing does to them (Olby et al. 2026; Chapagain et al. 2018; Ray et al. 2021; Mondino et al. 2024; Adams et al. 2016; Sarver et al. 2022), a description of the canine and feline gut community and evidence that age and diet reshape gene expression in ageing dogs (Deng and Swanson 2015), and a growing set of tools to modulate that community (Wilson and Swanson 2024). The bridge from the mouse-and-rabbit longevity science to the canine-and-feline ageing reality is built at both ends and unfinished in the middle.

This is not a hedge, it is the current state of the field, and saying so plainly is more useful to a vet or an owner than a confident claim the data cannot support. The right posture is neither dismissal nor hype. The mechanism is plausible and partly proven in other species; the companion-animal proof is missing; the way to get it is to measure.

Can you change the ageing gut? What the biotics evidence shows.

If the ageing gut can be nudged, the obvious tools are dietary and microbial, grouped under the term biotics. The four categories are worth keeping distinct because they do different things. Probiotics are live micro-organisms given in the hope they establish or transiently benefit the host. Prebiotics are substrates, usually fermentable fibres, that feed the bacteria already present and shift what they produce. Synbiotics combine the two. Postbiotics are the beneficial products themselves, such as short-chain fatty acids or inactivated microbial components, given directly rather than grown in the gut. Reviewing their influence on the gut microbiome of dogs and cats, Wilson and Swanson (2024) set out both the rationale and its limits. Biotics can shift the canine and feline community, support short-chain fatty acid production, and modulate immune and barrier function, and specific strains and fibres have measurable effects in dogs and cats.

Diet is the strongest routine lever an owner has over the gut, and the senior-care literature already leans on it: both the feline senior guidelines (Ray et al. 2021) and the canine cognitive literature (Chapagain et al. 2018) point to highly digestible diets, antioxidants and omega-3 fatty acids for older animals, though for cognition the benefit is attributed to the nutrients and to enrichment rather than to the microbiome as such.

The limits are real and worth stating. Much of the companion-animal biotics evidence concerns short-term gastrointestinal outcomes rather than the slow endpoints of ageing, the studies are often small, and none demonstrates a healthspan or lifespan benefit in dogs or cats. A supplement that shifts a stool sample's composition for a fortnight is not the same as one that changes how an animal ages over a decade. The reasonable position is that diet and biotics can change the ageing gut, that some of those changes point in a direction the ageing literature would predict is favourable, and that the outcome data in dogs and cats are not yet there to promise more.

Where BAARK fits.

The bottom line.

Dogs and cats are living longer, and the years we are adding come with cognitive decline, frailty, falling quality of life and a rising burden of chronic disease. The gut microbiome is a credible lever on how animals age. In mice, transplanting a young microbiome extended lifespan, and a single organism, Akkermansia muciniphila, did much of the work; in rabbits and in people, longer lives carry a more diverse community and a recognisable set of the same organisms; and the mechanisms that would carry a gut effect to the rest of the body, the barrier, lipopolysaccharide, short-chain fatty acids and bile acids, are general mammalian biology. What is missing is the proof in dogs and cats themselves. No study yet shows that changing a companion animal's microbiome changes how it ages. The mechanism is real and the companion-animal answer is still being written, which is precisely why the sensible first move is to measure the ageing gut rather than to make promises about it.